Related Experiment Video

Updated: Apr 27, 2026

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.9K

Pediatric fatty liver disease: role of ethnicity and genetics

Pierluigi Marzuillo1, Emanuele Miraglia del Giudice1, Nicola Santoro1

  • 1Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Department of Women and Children and General and Specialized Surgery, Seconda Università degli Studi di Napoli, 80138 Naples, Italy.

World Journal of Gastroenterology
|June 27, 2014
PubMed

Insights

Non-alcoholic fatty liver disease (NAFLD) is increasingly common in children, with genetic factors like the PNPLA3 gene significantly influencing susceptibility and disease progression. Ethnicity also plays a role in NAFLD prevalence among pediatric populations.

Area of Science:

  • Hepatology
  • Genetics
  • Pediatrics

Background:

  • Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver condition in children, with prevalence doubling in 20 years, linked to rising childhood obesity.
  • NAFLD affects 3-11% of children, rising to 46% in overweight/obese youth.
  • Hepatic steatosis prevalence differs across ethnic groups, with Hispanics showing the highest rates, followed by Caucasians and African-Americans.

Purpose of the Study:

  • To review current knowledge on the role of ethnicity and genetics in the pathogenesis of pediatric fatty liver.
  • To highlight the genetic predisposition to NAFLD.
  • To discuss the impact of genetic variants on NAFLD development.

Main Methods:

  • Literature review of studies on pediatric NAFLD.
  • Analysis of genetic association studies.
  • Examination of ethnic variations in NAFLD prevalence.

Main Results:

  • The patatin-like phospholipase containing domain 3 (PNPLA3) gene is a key genetic factor in NAFLD pathogenesis.
  • Genetic variants, identified since 2008, contribute significantly to fatty liver disease development.
  • Ethnic background is associated with varying NAFLD prevalence, suggesting a genetic component.

Conclusions:

  • Ethnicity and genetic factors, particularly the PNPLA3 gene, are crucial in understanding the pathogenesis of pediatric NAFLD.
  • Genetic predisposition plays a significant role in the increasing prevalence of NAFLD in children.
  • Further research into genetic and ethnic factors is warranted for effective NAFLD management in pediatric populations.

Keywords:
Apolipoprotein C3 geneEthnicityFarnesyl-diphosphate farnesyltransferase 1Glucokinase regulatory proteinInsulin resistanceNon alcoholic fatty liver diseaseObesityPatatin like phospholipase containing domain 3 gene

More Related Videos

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

15.9K
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

1.2K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
405
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
13
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157